<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Design Caffeine&#187; Inventions</title>
	<atom:link href="http://www.designcaffeine.com/category/inventions/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.designcaffeine.com</link>
	<description>We design what works.</description>
	<lastBuildDate>Fri, 27 Jan 2012 07:37:25 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>US Patent #6677343: Substituted Piperazine Compounds</title>
		<link>http://www.designcaffeine.com/articles/inventions/us-patent-6677343-substituted-piperazine-compounds/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=us-patent-6677343-substituted-piperazine-compounds</link>
		<comments>http://www.designcaffeine.com/articles/inventions/us-patent-6677343-substituted-piperazine-compounds/#comments</comments>
		<pubDate>Thu, 21 Jan 2010 06:14:45 +0000</pubDate>
		<dc:creator>Greg Nudelman</dc:creator>
				<category><![CDATA[Inventions]]></category>
		<category><![CDATA[Biochemistry]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceutical]]></category>

		<guid isPermaLink="false">http://www.designcaffeine.com/?p=250</guid>
		<description><![CDATA[Key Ranolazine patent for CV Therapeutics/Gilead: a novel class of compounds that are useful in the treatment of cardiovascular diseases including arrhythmias, angina, congestive heart disease, and myocardial infarction.]]></description>
			<content:encoded><![CDATA[<p>Novel compounds of the general formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal&#8217;s (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.</p>
<p><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=1&amp;f=G&amp;l=50&amp;co1=AND&amp;d=PTXT&amp;s1=6677343.PN.&amp;OS=PN/6677343&amp;RS=PN/6677343" target="new">Granted by the US Patent Office February 22, 2001 ⇒</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.designcaffeine.com/articles/inventions/us-patent-6677343-substituted-piperazine-compounds/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>US Patent #6180615: Propargyl Phenyl Ether A2A Receptor Agonists</title>
		<link>http://www.designcaffeine.com/articles/inventions/us-patent-6180615-propargyl-phenyl-ether-a2a-receptor-agonists/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=us-patent-6180615-propargyl-phenyl-ether-a2a-receptor-agonists</link>
		<comments>http://www.designcaffeine.com/articles/inventions/us-patent-6180615-propargyl-phenyl-ether-a2a-receptor-agonists/#comments</comments>
		<pubDate>Thu, 21 Jan 2010 06:13:21 +0000</pubDate>
		<dc:creator>Greg Nudelman</dc:creator>
				<category><![CDATA[Inventions]]></category>
		<category><![CDATA[Biochemistry]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceutical]]></category>

		<guid isPermaLink="false">http://www.designcaffeine.com/?p=247</guid>
		<description><![CDATA[Key CV Therapeutics/Gilead patent for A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.]]></description>
			<content:encoded><![CDATA[<p>2-adenosine propargyl phenyl ether compositions having the following formula: ##STR1## and methods for using the compositions as A.sub.2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.</p>
<p><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=1&amp;f=G&amp;l=50&amp;co1=AND&amp;d=PTXT&amp;s1=6180615.PN.&amp;OS=PN/6180615&amp;RS=PN/6180615" target="new">Granted by the US Patent Office June 22, 1999 ⇒</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.designcaffeine.com/articles/inventions/us-patent-6180615-propargyl-phenyl-ether-a2a-receptor-agonists/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>US Patent #6677336: Substituted Piperazine Compounds</title>
		<link>http://www.designcaffeine.com/articles/inventions/us-patent-6677336-substituted-piperazine-compounds/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=us-patent-6677336-substituted-piperazine-compounds</link>
		<comments>http://www.designcaffeine.com/articles/inventions/us-patent-6677336-substituted-piperazine-compounds/#comments</comments>
		<pubDate>Thu, 21 Jan 2010 06:11:40 +0000</pubDate>
		<dc:creator>Greg Nudelman</dc:creator>
				<category><![CDATA[Inventions]]></category>
		<category><![CDATA[Biochemistry]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceutical]]></category>

		<guid isPermaLink="false">http://www.designcaffeine.com/?p=245</guid>
		<description><![CDATA[Key Ranolazine patent for CV Therapeutics/Gilead: a novel class of compounds that are useful in the treatment of cardiovascular diseases including arrhythmias, angina, congestive heart disease, and myocardial infarction.]]></description>
			<content:encoded><![CDATA[<p>Novel compounds of the general formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal&#8217;s (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.</p>
<p><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&amp;Sect2=HITOFF&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&amp;r=1&amp;f=G&amp;l=50&amp;co1=AND&amp;d=PTXT&amp;s1=6677336.PN.&amp;OS=PN/6677336&amp;RS=PN/6677336" target="new">Granted by the US Patent Office February 22, 2001 ⇒</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.designcaffeine.com/articles/inventions/us-patent-6677336-substituted-piperazine-compounds/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

